Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
connexin 43 (M1) antibody
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at San Antonio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravitreal
01
Overview
connexin 43 (M1) antibody (Cx43(M1)) is a mouse monoclonal antibody that selectively blocks connexin 43 (Cx43) hemichannels without disrupting gap junction communication. Developed by the Jiang Laboratory at the University of Texas Health Science Center at San Antonio (UT Health San Antonio) in collaboration with Abmart, the antibody targets the second extracellular loop of Cx43. By inhibiting Cx43 hemichannels, the antibody blocks the release of small signaling molecules such as prostaglandin E2 (PGE2) and adenosine triphosphate (ATP). It is being investigated in preclinical models for various indications, including osteoarthritis, spinal cord injury, optic nerve injury (neuroprotection of retinal ganglion cells), posterior capsule opacification (PCO), and bone remodeling/osteoporosis.
- Other names
- anti-connexin 43 (M1) antibodyanti-Cx43(M1) antibodyconnexin 43 (M1) monoclonal antibodyM1 antibodyM-1 antibodyM 1 antibody
02
Targets
GJA1 (Connexin43 Hemichannel)
Beyond the preview
Go deeper on connexin 43 (M1) antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on connexin 43 (M1) antibody.